The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint

Affiliations

¹ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA. Electronic address: nicholas.richardson@fda.hhs.gov.
² Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
³ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD 20993, USA.

Nicholas C Richardson et al. Lancet Oncol. 2022 May.

. 2022 May;23(5):563-566.

doi: 10.1016/S1470-2045(22)00200-5. Epub 2022 Apr 14.

¹ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA. Electronic address: nicholas.richardson@fda.hhs.gov.
² Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
³ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD 20993, USA.

No abstract available

Conflict of interest statement

We declare no competing interests.

PI3K inhibitors in haematological malignancies.
Benjamin DJ, Prasad V. Benjamin DJ, et al. Lancet Oncol. 2022 Aug;23(8):e362-e363. doi: 10.1016/S1470-2045(22)00260-1. Lancet Oncol. 2022. PMID: 35901824 No abstract available.
PI3K inhibitors in haematological malignancies.
Brown JR, Danilov AV, LaCasce AS, Davids MS. Brown JR, et al. Lancet Oncol. 2022 Aug;23(8):e364. doi: 10.1016/S1470-2045(22)00300-X. Lancet Oncol. 2022. PMID: 35901825 No abstract available.
PI3K inhibitors in haematological malignancies.
Matasar MJ, Hiemeyer F, Childs BH, Zinzani PL. Matasar MJ, et al. Lancet Oncol. 2022 Aug;23(8):e365. doi: 10.1016/S1470-2045(22)00332-1. Lancet Oncol. 2022. PMID: 35901826 No abstract available.